| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Allogene Therapeutics, Inc.
13D/A
ALLO · 019770106
|
9.0% |
2/13/2026
Event 11/6/2025
|
||||
|
Haleon plc
13D/A
HLN · 405552100
|
0% |
3/24/2025
Event 3/21/2025
|
||||
| Schedule 13G · 6 securities · passive | ||||||
|
Trex Bio, Inc.
13G
TRXB · 89531N100
|
7.2% |
10/16/2026
Event 10/8/2026
|
||||
| Pfizer Inc. (13-5315170) | 7.2% | |||||
| Pfizer Ventures (US) LLC (82-5524518) | 4.6% | |||||
|
ORIC Pharmaceuticals, Inc.
13G/A
ORIC · 68622P109
|
3.3% |
5/12/2026
Event 3/31/2026
|
||||
|
Q32 Bio Inc.
13G/A
QTTB · 746964105
|
2.3% |
2/13/2026
Event 12/31/2024
|
||||
|
NextCure, Inc.
13G/A
NXTC · 65343E108
|
3.0% |
2/13/2026
Event 12/31/2025
|
||||
| Pfizer Inc. (IRS Identification No.: 13-5315170) | 3.0% | |||||
| Pfizer Ventures (US) LLC (IRS Indentification No. 82-5524518 ) | 2.5% | |||||
|
Zura Bio Limited
13G/A
ZURA · G9TY5A101
|
4.6% |
2/12/2025
Event 12/31/2024
|
||||
|
Cardiff Oncology, Inc.
13G/A
CRDF · 14147L108
|
3.6% |
2/12/2025
Event 12/31/2024
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.